|
|
Early immunologic rebound in natalizumab-associated PML has worse survival and neurologic outcome. PLEX/IA may accelerate IRIS and its impact on the final outcome is unclear. Cortico-steroid therapy provides a modest benefit and needs to be systematically studied in a controlled manner in the management of natalizumab-associated PML-IRIS. |
|